13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001534261
Total reported value
$2.0B
$2.0B
33 檔
37.5%
At the close of Q2 2025, Casdin Capital, LLC disclosed equity holdings valued at approximately $2.0B, spread across 33 reported holdings.
In Q2 2025, Casdin Capital, LLC adopted a defensive or profit-taking posture, trimming 12 positions and completely liquidating 12 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including WGS, BLFS, RVMD) accounted for 37.5% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | WGS | Genedx Holdings CORP | Stock-Other | 29.48% | -1.88% | — | |
| 2 | BLFS | Biolife Solutions Inc | Stock-Other | 15.12% | -2.03% | -11.48% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 9.68% | +5.18% | -21.90% | |
| 4 | LAB | Standard Biotools Inc | Stock-Other | 8.31% | -2.52% | — | |
| 5 | ILMN | Illumina Inc | Stock-Healthcare | 5.60% | -0.29% | +8.40% | |
| 6 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 4.59% | — | -13.20% | |
| 7 | ✓ | Verve Therapeutics Inc | Stock-Other | 4.19% | — | +2.50% | |
| 8 | RLAY | Relay Therapeutics Inc | Stock-Other | 3.59% | +4.16% | +25.28% | |
| 9 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 2.42% | -0.75% | -32.08% | |
| 10 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.31% | -1.13% | +75.00% | |
| 11 | BEAM | Beam Therapeutics Inc | Stock-Other | 2.25% | -0.12% | +1.71% | |
| 12 | NGNE | Neurogene Inc | Stock-Other | 1.76% | +0.26% | — | |
| 13 | CDXS | Codexis Inc | Stock-Other | 1.60% | — | -11.11% | |
| 14 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.54% | +0.42% | NEW | |
| 15 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.13% | -0.05% | -10.10% | |
| 16 | HIMS | Hims & Hers Health Inc | Stock-Healthcare | 1.04% | +0.11% | +15.00% | |
| 17 | MAZE | Maze Therapeutics Inc | Stock-Other | 0.85% | -0.46% | -19.81% | |
| 18 | VCYT | Veracyte Inc | Stock-Other | 0.68% | +0.14% | — | |
| 19 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.60% | — | — | |
| 20 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.55% | — | +2.36% | |
| 21 | SEPN | Septerna Inc | Stock-Other | 0.53% | -0.08% | — | |
| 22 | GH | Guardant Health Inc | Stock-Healthcare | 0.47% | -0.81% | -60.00% | |
| 23 | EXK | Exact Sciences CORP | Stock-Materials | 0.44% | — | -77.78% | |
| 24 | PRME | Prime Medicine Inc | Stock-Other | 0.35% | -0.25% | +326.82% | |
| 25 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.30% | — | -60.00% | |
| 26 | ABSI | Absci CORP | Stock-Other | 0.23% | +0.34% | — | |
| 27 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.08% | -0.01% | — | |
| 28 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.08% | -0.01% | — | |
| 29 | IPSC | Century Therapeutics Inc | Stock-Other | 0.06% | -0.06% | -61.77% | |
| 30 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 0.05% | -0.03% | — | |
| 31 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 0.04% | — | — | |
| 32 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.04% | — | — | |
| 33 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.02% | -0.01% | -94.62% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | WGS | Genedx Holdings CORP | +4.1% | — | Unchanged |
| 2 | ✓ | Verve Therapeutics Inc | +2.7% | +2.50% | Add |
| 3 | ILMN | Illumina Inc | +1.7% | +8.40% | Add |
| 4 | RLAY | Relay Therapeutics Inc | +1.6% | +25.28% | Add |
| 5 | LAB | Standard Biotools Inc | +1.6% | — | Unchanged |
| 6 | GPCR | Structure Therapeutics Inc | +1.3% | +75.00% | Add |
| 7 | LLY | Eli Lilly & Co | +0.6% | NEW | New buy |
| 8 | HIMS | Hims & Hers Health Inc | +0.6% | +15.00% | Add |
| 9 | NGNE | Neurogene Inc | +0.5% | — | Unchanged |
| 10 | PRME | Prime Medicine Inc | +0.3% | +326.82% | Add |
| 11 | SEPN | Septerna Inc | +0.3% | — | Unchanged |
| 12 | DNLI | Denali Therapeutics Inc | 0% | -10.10% | Trim |
| 13 | ABSI | Absci CORP | 0% | — | Unchanged |
| 14 | DNA | Ginkgo Bioworks Holdings Inc | 0% | — | Unchanged |
| 15 | VCYT | Veracyte Inc | 0% | — | Unchanged |
| 16 | PACB | Pacific Biosciences Of Calif | 0% | — | Unchanged |
| 17 | RXRX | Recursion Pharmaceuticals-a | 0% | — | Unchanged |
| 18 | GLUE | Monte Rosa Therapeutics Inc | 0% | — | Unchanged |
| 19 | MAZE | Maze Therapeutics Inc | — | -19.81% | Trim |
| 20 | TNGX | Tango Therapeutics Inc | 0% | EXIT | Sold out |
| 21 | KRON1USD | Kronos Bio Inc | 0% | EXIT | Sold out |
| 22 | BEAM | Beam Therapeutics Inc | 0% | +1.71% | Add |
| 23 | CTNM | Contineum Therapeutics Inc-a | 0% | — | Unchanged |
| 24 | IPSC | Century Therapeutics Inc | -0.1% | -61.77% | Trim |
| 25 | SNDX | Syndax Pharmaceuticals Inc | -0.1% | +2.36% | Add |
| 26 | DYN | Dyne Therapeutics Inc | -0.1% | EXIT | Sold out |
| 27 | CDXS | Codexis Inc | -0.2% | -11.11% | Trim |
| 28 | TDOC | Teladoc Health Inc | -0.2% | EXIT | Sold out |
| 29 | ALNY | Alnylam Pharmaceuticals Inc | -0.2% | -32.08% | Trim |
| 30 | SLDB | Solid Biosciences Inc | -0.2% | EXIT | Sold out |
| 31 | TNYA | Tenaya Therapeutics Inc | -0.3% | -94.62% | Trim |
| 32 | AGIO | Agios Pharmaceuticals Inc | -0.3% | -60.00% | Trim |
| 33 | VSTM | Verastem Inc | -0.3% | EXIT | Sold out |
| 34 | RNAGBP | Avidity Biosciences Inc | -0.3% | -13.20% | Trim |
| 35 | GH | Guardant Health Inc | -0.4% | -60.00% | Trim |
| 36 | MRNA | Moderna Inc | -0.5% | EXIT | Sold out |
| 37 | GEHC | GE Healthcare Technology | -0.7% | EXIT | Sold out |
| 38 | TSVT* | 2seventy Bio Inc | -0.8% | EXIT | Sold out |
| 39 | ONC | Beone Medicines Ltd-adr | -0.9% | EXIT | Sold out |
| 40 | EXK | Exact Sciences CORP | -1% | -77.78% | Trim |
| 41 | RVMD | Revolution Medicines Inc | -1% | -21.90% | Trim |
| 42 | BLFS | Biolife Solutions Inc | -1.1% | -11.48% | Trim |
| 43 | NTLA | Intellia Therapeutics Inc | -1.2% | EXIT | Sold out |
| 44 | 2655787D | Blueprint Medicines CORP | -2.4% | EXIT | Sold out |
| 45 | SRPT | Sarepta Therapeutics Inc | -3.2% | +9.92% | Add |
According to official SEC Form 13F filings, Casdin Capital, LLC reported a total U.S. public equity portfolio value of $2.0B across 33 disclosed positions in Q2 2025.
During Q2 2025, Casdin Capital, LLC's top holdings by market value included WGS (29.5%)、BLFS (15.1%)、RVMD (9.7%). The largest single position, WGS, represented 29.5% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
LLY
市值: $6.6M
Top Position Liquidated / Trimmed
2655787D
前期市值: $28.9M
In Q2 2025, Casdin Capital, LLC made 34 total portfolio adjustments, initiating 1 new buys, adding to 9 positions, trimming 12 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.